Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment

被引：0
|
作者：
Gravalos, C.
Sastre, J.
Aranda, E.
Massuti, B.
Vega-Villegas, M. E.
Gomez, A.
Varella-Garcia, M.
Jimeno, A.
Diaz-Rubio, E.
Hidalgo, M.
机构：
[1] Hosp 12 Octubre, Madrid, Spain
[2] Hosp Clin San Carlos, Madrid, Spain
[3] Hosp Reina Sofia, Cordoba, Spain
[4] Hosp Gen Univ Alicante, Alicante, Spain
[5] Hosp Univ Marques de Valdecilla, Santander, Spain
[6] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA
[7] Johns Hopkins Univ, Baltimore, MD USA
[8] Hosp Monteprincipe, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页数：1
相关论文
共 50 条
  • [21] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [22] Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.
    Fountzilas, Christos
    Rosario, Spencer
    Withers, Henry G.
    Mukherjee, Sarbajit
    Bajor, David L.
    Saltzman, Joel N.
    Wang, Chong
    Attwood, Kristopher
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    Iyer, Renuka V.
    Boland, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 178 - 178
  • [23] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
    Cervantes, A.
    Macarulla, T.
    Martinelli, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Stroh, C.
    Nippgen, J.
    Baselga, J.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Single-agent docetaxel (TXT) as first-line treatment in metastatic breast cancer (MBC)
    Guarneri, D.
    Ratti, R.
    Venturino, A.
    Addamo, G.
    Coccorullo, Z.
    Colloca, G.
    Campora, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience
    Davidson, NG
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 6 - 10
  • [27] Capecitabine single agent or in combination in the routine first-line treatment of a predominantly elderly population with metastatic colorectal cancer (MCRC)
    Schroeder, J.
    Goehler, T.
    Grothe, W.
    Tschechne, B.
    Valdix, A. R.
    Harich, H. D.
    Kluensch, F.
    Hofheinz, R. D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 337 - 337
  • [28] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    De Braud, F. G.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer.: Preliminary results of a TTD phase II study
    Sastre, Javier
    Aranda, Enrique
    Gravalos, Cristina
    Massuti, Bartomeu
    Vega-Villegas, M. Eugenia
    Soler, Gemma
    Carrato, Alfredo
    Abad, Albert
    Gomez, Auxiladora
    Diaz-Rubio, Eduardo
    ANNALS OF ONCOLOGY, 2006, 17 : 114 - 114
  • [30] First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study
    Garcia Alfonso, P.
    Valladares-Ayerbes, M.
    Munoz Luengo, J.
    Pimentel, P.
    Vieitez, J. M.
    Cruz Hernandez, J. J.
    Llanos, M.
    Garcia Giron, C.
    Salud Salvia, A.
    Lloansi Vila, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 183 - 183
12345